R1 RCM (NASDAQ:RCM) PT Lowered to $15.00

R1 RCM (NASDAQ:RCM - Get Free Report) had its target price lowered by stock analysts at Canaccord Genuity Group from $16.00 to $15.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a "buy" rating on the healthcare provider's stock. Canaccord Genuity Group's price objective would indicate a potential upside of 22.25% from the company's previous close.

A number of other research firms also recently commented on RCM. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price objective on shares of R1 RCM in a research note on Wednesday, April 10th. Leerink Partnrs reiterated an "outperform" rating on shares of R1 RCM in a report on Monday, February 26th. Evercore ISI restated an "in-line" rating and set a $16.00 target price (up from $12.00) on shares of R1 RCM in a report on Wednesday, February 28th. Truist Financial reaffirmed a "hold" rating and issued a $16.00 price target on shares of R1 RCM in a report on Monday, April 1st. Finally, Morgan Stanley restated an "overweight" rating and issued a $17.00 target price on shares of R1 RCM in a report on Tuesday, March 26th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $16.71.

R1 RCM Trading Down 4.4 %

Shares of R1 RCM stock traded down $0.57 during trading on Thursday, hitting $12.27. 9,101,789 shares of the stock were exchanged, compared to its average volume of 3,537,086. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.57. R1 RCM has a 12 month low of $8.87 and a 12 month high of $18.70. The stock's fifty day moving average is $12.88 and its 200 day moving average is $11.46.

R1 RCM (NASDAQ:RCM - Get Free Report) last posted its earnings results on Wednesday, May 8th. The healthcare provider reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). R1 RCM had a net margin of 0.15% and a return on equity of 0.12%. The business had revenue of $603.90 million during the quarter, compared to analyst estimates of $612.88 million. The business's quarterly revenue was up 10.7% on a year-over-year basis. On average, research analysts forecast that R1 RCM will post -0.05 earnings per share for the current year.

Insider Buying and Selling at R1 RCM

In other news, President John M. Sparby sold 10,046 shares of the company's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $14.33, for a total transaction of $143,959.18. Following the completion of the transaction, the president now directly owns 265,986 shares in the company, valued at $3,811,579.38. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 36.80% of the company's stock.

Institutional Trading of R1 RCM

A number of hedge funds have recently modified their holdings of RCM. QRG Capital Management Inc. acquired a new position in shares of R1 RCM in the first quarter valued at $132,000. Texas Permanent School Fund Corp increased its stake in R1 RCM by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 172,179 shares of the healthcare provider's stock valued at $2,218,000 after acquiring an additional 2,135 shares during the period. BW Gestao de Investimentos Ltda. acquired a new position in R1 RCM in the first quarter worth about $11,513,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in R1 RCM by 76.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 396,830 shares of the healthcare provider's stock worth $5,111,000 after purchasing an additional 171,400 shares during the period. Finally, Retirement Systems of Alabama boosted its holdings in R1 RCM by 0.3% during the first quarter. Retirement Systems of Alabama now owns 247,476 shares of the healthcare provider's stock valued at $3,187,000 after purchasing an additional 856 shares in the last quarter. Institutional investors own 61.10% of the company's stock.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.